Meeting of the Uniform Formulary Beneficiary Advisory Panel, 79344 [2010-31791]

Download as PDF 79344 Federal Register / Vol. 75, No. 243 / Monday, December 20, 2010 / Notices numbers for the CFTC’s regulations were published on December 30, 1981. See 46 FR 63035 (Dec. 30, 1981). The Federal Register notice with a 60-day comment period soliciting comments on this collection of information was published on August 14, 2007 (72 FR 45420). Burden statement: The respondent burden for this collection is estimated to average .10 hours per response to file the brief written statement. This estimate includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; and transmit or otherwise disclose the information. Respondents/Affected Entities: 3. Estimated number of responses: 4.5. Estimated total annual burden on respondents: .10 hours. Frequency of collection: On occasion. Send comments regarding the burden estimated or any other aspect of the information collection, including suggestions for reducing the burden, to the addresses listed below. Please refer to OMB Control No. 3038–0025 in any correspondence. John P. Dolan, Office of General Counsel, U.S. Commodity Futures Trading Commission, 1155 21st Street, NW., Washington, DC 20581 and Office of Information and Regulatory Affairs, Office of Management and Budget, Attention: Desk Officer for CFTC, 725 17th Street, Washington, DC 20503. Dated: December 15, 2010. David A. Stawick, Secretary of the Commission. [FR Doc. 2010–31900 Filed 12–17–10; 8:45 am] BILLING CODE P DEPARTMENT OF DEFENSE Office of the Secretary Meeting of the Uniform Formulary Beneficiary Advisory Panel Assistant Secretary of Defense (Health Affairs), DoD. ACTION: Notice of meeting. jlentini on DSKJ8SOYB1PROD with NOTICES AGENCY: Under the provisions of the Federal Advisory Committee Act of 1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the SUMMARY: VerDate Mar<15>2010 17:18 Dec 17, 2010 Jkt 223001 Department of Defense announces the following Federal Advisory Committee Meeting of the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel). DATES: January 6, 2011, from 9 a.m.–12 p.m. ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004. FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Stacia Spridgen, Designated Federal Officer, Uniform Formulary Beneficiary Advisory Panel 2450 Stanley Road, Suite 208, Ft. Sam Houston, TX 78234–6102, Telephone: (210) 295–127, Fax: (210) 295–2789, Email Address: Baprequests@tma.osd.mil. SUPPLEMENTARY INFORMATION: Purpose of Meeting: The Panel will review and comment on recommendations made to the Director, TRICARE Management Activity, by the Pharmacy and Therapeutics Committee regarding the Uniform Formulary. Meeting Agenda: 1. Sign-In. 2. Welcome and Opening Remarks. 3. Public Citizen Comments. 4. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item). a. Non-Insulin Anti-Diabetic Drugs. b. Designated Newly Approved Drugs in Already-Reviewed Classes. c. Pertinent Utilization Management Issues. d. Drugs Recommended for NonFormulary Placement Due to NonCompliance with the National Defense Authorization Act for Fiscal Year 2008, Section 703. 5. Panel Discussions and Vote. Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and Title 41, Code of Federal Regulations (CFR), 102– 3.140 through 102–3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly. Administrative Work Meeting: Prior to the public meeting, the Panel will conduct an Administrative Work Meeting from 8 a.m. to 9 a.m. to discuss administrative matters of the Panel. The Administrative Work Meeting will be held at the Naval Heritage Center, 701 Pennsylvania Avenue, NW., Washington, DC, 20004. Pursuant to 41 CFR 102–3.160, the Administrative Work Meeting will be closed to the public. Written Statements: Pursuant to 41 CFR 102–3.105(j) and 102–3.140, the public or interested organizations may PO 00000 Frm 00011 Fmt 4703 Sfmt 9990 submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel’s Designated Federal Officer (DFO). The DFO’s contact information can be obtained from the General Services Administration’s Federal Advisory Committee Act Database—https:// www.fido.gov/facadatabase/public.asp. Written statements that do not pertain to the scheduled meeting of the Panel may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting, then these statements must be submitted no later than five business days prior to the meeting in question. The DFO will review all submitted written statements and provide copies to all the committee members. Public Comments: In addition to written statements, the Panel will set aside one hour for individuals or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice; but if they still want to address the Panel, then they will be afforded the opportunity to register to address the Panel. The Panel’s DFO will have a ‘‘Sign-Up Roster’’ available at the Panel meeting, for registration on a first-come, first-serve basis. Those wishing to address the Panel will be given no more than five minutes to present their comments, and at the end of the onehour time period, no further public comments will be accepted. Anyone who signs up to address the Panel, but is unable to do so due to the time limitation, may submit comments in writing; however, he or she must understand that written comments may not be reviewed prior to the Panel’s deliberation. Accordingly, the Panel recommends that individuals and interested groups consider submitting written statements instead of addressing the Panel. Dated: December 14, 2010. Morgan F. Park, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2010–31791 Filed 12–17–10; 8:45 am] BILLING CODE 5001–06–P E:\FR\FM\20DEN1.SGM 20DEN1

Agencies

[Federal Register Volume 75, Number 243 (Monday, December 20, 2010)]
[Notices]
[Page 79344]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-31791]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and 
the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) 
the Department of Defense announces the following Federal Advisory 
Committee Meeting of the Uniform Formulary Beneficiary Advisory Panel 
(hereafter referred to as the Panel).

DATES: January 6, 2011, from 9 a.m.-12 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Stacia Spridgen, 
Designated Federal Officer, Uniform Formulary Beneficiary Advisory 
Panel 2450 Stanley Road, Suite 208, Ft. Sam Houston, TX 78234-6102, 
Telephone: (210) 295-127, Fax: (210) 295-2789, E-mail Address: 
Baprequests@tma.osd.mil.

SUPPLEMENTARY INFORMATION:
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director, TRICARE Management Activity, by 
the Pharmacy and Therapeutics Committee regarding the Uniform 
Formulary.
    Meeting Agenda:
    1. Sign-In.
    2. Welcome and Opening Remarks.
    3. Public Citizen Comments.
    4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item).
    a. Non-Insulin Anti-Diabetic Drugs.
    b. Designated Newly Approved Drugs in Already-Reviewed Classes.
    c. Pertinent Utilization Management Issues.
    d. Drugs Recommended for Non-Formulary Placement Due to Non-
Compliance with the National Defense Authorization Act for Fiscal Year 
2008, Section 703.
    5. Panel Discussions and Vote.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
Title 41, Code of Federal Regulations (CFR), 102-3.140 through 102-
3.165, and the availability of space, this meeting is open to the 
public. Seating is limited and will be provided only to the first 220 
people signing-in. All persons must sign-in legibly.
    Administrative Work Meeting: Prior to the public meeting, the Panel 
will conduct an Administrative Work Meeting from 8 a.m. to 9 a.m. to 
discuss administrative matters of the Panel. The Administrative Work 
Meeting will be held at the Naval Heritage Center, 701 Pennsylvania 
Avenue, NW., Washington, DC, 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140, 
the public or interested organizations may submit written statements to 
the membership of the Panel at any time or in response to the stated 
agenda of a planned meeting. Written statements should be submitted to 
the Panel's Designated Federal Officer (DFO). The DFO's contact 
information can be obtained from the General Services Administration's 
Federal Advisory Committee Act Database--https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting, then 
these statements must be submitted no later than five business days 
prior to the meeting in question. The DFO will review all submitted 
written statements and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside one hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting, for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than five minutes to present 
their comments, and at the end of the one-hour time period, no further 
public comments will be accepted. Anyone who signs up to address the 
Panel, but is unable to do so due to the time limitation, may submit 
comments in writing; however, he or she must understand that written 
comments may not be reviewed prior to the Panel's deliberation. 
Accordingly, the Panel recommends that individuals and interested 
groups consider submitting written statements instead of addressing the 
Panel.

    Dated: December 14, 2010.
Morgan F. Park,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2010-31791 Filed 12-17-10; 8:45 am]
BILLING CODE 5001-06-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.